West Paces Advisors’s Bio-Rad Laboratories Class A BIO Stock Holding History

West Paces Advisors’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-1	Closed	-$329	–	565
2024 Q4	$329	Sell	1 -4	-80%	-$1.36K	﹤0.01%	536
2024 Q3	$1.67K	Buy	+5	New	+$1.59K	﹤0.01%	448
2024 Q2	–	Sell	-6	Closed	-$2.08K	–	570
2024 Q1	$2.08K	Hold	6	–	–	﹤0.01%	450
2023 Q4	$1.94K	Buy	6 +1	+20%	+$313	﹤0.01%	464
2023 Q3	$1.79K	Buy	5 +4	+400%	+$1.54K	﹤0.01%	433
2023 Q2	$379	Sell	1 -1	-50%	-$407	﹤0.01%	531
2023 Q1	$958	Buy	2 +1	+100%	+$468	﹤0.01%	510
2022 Q4	$420	Buy	+1	New	+$404	﹤0.01%	513

Other funds holding BIO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

VAM

Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

West Paces Advisors's BIO Position: Q1 2025 in Review

West Paces Advisors sold out of Bio-Rad Laboratories Class A (BIO) in Q1 2025, closing a stake of 1 share — an estimated $329 sold.

West Paces Advisors first reported a position in BIO in Q4 2022 and held it in 8 quarters. The position peaked at $2.08K in Q1 2024. 436 funds tracked by Wall St. Rank hold BIO as of Q1 2025.

West Paces Advisors reported no remaining Bio-Rad Laboratories Class A position as of Q1 2025 after selling out during the quarter.
West Paces Advisors sold 1 Bio-Rad Laboratories Class A share in Q1 2025, an estimated $329.
West Paces Advisors first reported a position in Bio-Rad Laboratories Class A in Q4 2022 and held it in 8 quarters.
West Paces Advisors's Bio-Rad Laboratories Class A position peaked at $2.08K in Q1 2024.
436 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2025.

Based on West Paces Advisors's 13F filing for Q1 2025, filed 15 Apr 2025.